Examining the Use of Non-Invasive Inhaled Nitric Oxide to Reduce Chronic Lung Disease in Premature Newborns
Recruitment status was Recruiting
Bronchopulmonary dysplasia (BPD) is a serious lung condition that affects premature newborns. The condition involves abnormal development of lung tissue and is characterized by inflammation and scarring in the lungs. Treatment with inhaled nitric oxide (iNO) may reduce the incidence of BPD and another commonly associated condition called pulmonary hypertension, which is high blood pressure in the vessels carrying blood to the lungs.. This study will determine if early treatment with low-dose iNO reduces the incidence of BPD, pulmonary hypertension, and death in premature newborns.
Drug: Inhaled Nitric Oxide (iNO)
Drug: Nitrogen (placebo)
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Prevention
|Official Title:||Non-invasive Inhaled Nitric Oxide in Premature Newborns|
- Combined endpoint of bronchopulmonary dysplasia and mortality [ Time Frame: Week 36 or earlier, if participants are discharged from the hospital ] [ Designated as safety issue: No ]
- Pulmonary hypertension [ Time Frame: Week 36 or earlier, if participants are discharged from the hospital ] [ Designated as safety issue: No ]
|Study Start Date:||January 2007|
|Estimated Study Completion Date:||June 2013|
|Estimated Primary Completion Date:||December 2012 (Final data collection date for primary outcome measure)|
Experimental: Inhaled Nitric Oxide (iNO)
Participants will receive a low concentration of iNO until they are 30 weeks corrected gestational age or for 14 days if they were born at 29 weeks or more.
Drug: Inhaled Nitric Oxide (iNO)
iNO will be delivered using the iNOVent device to provide 10 ppm proximally (yielding approximately 5 ppm to the posterior pharynx).
Placebo Comparator: Nitrogen (placebo)
Participants will receive nitrogen (placebo) while in the hospital.
Drug: Nitrogen (placebo)
Nitrogen will be delivered using the iNOVent device to provide 10 ppm proximally (yielding approximately 5 ppm to the posterior pharynx).
BPD is a serious lung condition that primarily affects premature newborns and newborns with low birth weights. iNO has been proven to be a safe and effective treatment for pulmonary hypertension and hypoxemic respiratory failure—both of which are abnormal lung conditions—in full-term newborns. However, in babies born prematurely, the effects of iNO on lung function are not well defined. Also, previous studies have mainly examined whether iNO reduces the incidence of BPD in newborns who are on mechanical ventilation. However, intubation and mechanical ventilation of premature newborns is now increasingly being avoided, and non-invasive support, including the use of nasal continuous positive airway pressure (NCPAP), is being used. Early treatment with low-dose iNO may reduce the incidence of BPD in premature newborns who do not require mechanical ventilation and intubation after delivery. The purpose of this study is to determine if low-dose, non-invasive iNO reduces the risk of BPD, pulmonary hypertension, and death in premature newborns who do not require mechanical ventilation.
This study will enroll premature newborns who require extra oxygen but do not require intubation or mechanical ventilation for respiratory failure in the first 72 hours of life. Participants will be randomly assigned to receive low-dose, non-invasive iNO or nitrogen (placebo) during their hospital stay. While hospitalized, participants' heart rate, blood oxygen level breathing rate, blood pressure, and medications will be monitored, and blood collection will occur at various times. Monitoring will continue until participants are 30 weeks corrected gestational age or for at least 14 days if participants are born at 29 weeks or more. All participants will undergo an ultrasound of the head when they are 7 days, 28 days, and 36 weeks of age. They will undergo an echocardiogram, which is an ultrasound of the heart, at 7 and 21 days of age and 4 weeks before the original expected due date. A chest x-ray will be performed before hospital discharge, and a breathing status test will be performed either 4 weeks before participants' original expected due date or before hospital discharge. Follow-up study visits will occur at Years 1 and 2, and will include a physical examination and developmental and behavioral testing. Another echocardiogram will also be performed at the Year 1 visit.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00955487
|Contact: John Kinsella, MD||303-724-2853||John.Kinsella@ucdenver.edu|
|Contact: Gary Cutter, PhDfirstname.lastname@example.org|
|United States, Alabama|
|University of Alabama at Birmingham||Active, not recruiting|
|Birmingham, Alabama, United States, 35242|
|United States, California|
|University of California San Diego||Recruiting|
|San Diego, California, United States, 92123|
|Contact: Neil Finer, MD|
|United States, Colorado|
|Children's Hospital and University Colorado Hospital||Recruiting|
|Aurora, Colorado, United States, 80045|
|Contact: John Kinsella, MD 303-724-2853 John.Kinsella@ucdenver.edu|
|Contact: Lucy Fashaw, RN, BSN 720-777-6745 Lucy.Fashaw@ucdenver.edu|
|United States, Illinois|
|Children's Memorial Hospital and Northwestern Memorial Hospital||Recruiting|
|Chicago, Illinois, United States, 60614|
|Contact: Robin Steinhorn, MD|
|United States, Ohio|
|Nationwide Children's Hospital||Recruiting|
|Columbus, Ohio, United States, 43205|
|Contact: Leif D Nelin, MD, FAAP|
|United States, Tennessee|
|Vanderbilt Children's Hospital||Recruiting|
|Nashville, Tennessee, United States, 37232|
|Contact: William F Walsh, MD|
|Principal Investigator:||John Kinsella, MD||Chidlren's Hospital and University of Colorado Hospital|